Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 36Recurrence 9Neoplasms, Plasma Cell 5Neoplasms 3Lymphoma, Non-Hodgkin 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Neoplasms 2Hematologic Diseases 2Blood Protein Disorders 2Thrombocythemia, Essential 1Sarcoma, Kaposi 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Polycythemia Vera 1Paraproteinemias 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Primary Effusion 1Leukemia, Myeloid, Acute 1Hypoxia 1Hodgkin Disease 1Corneal Diseases 1Carcinoma, Small Cell 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Proteostasis Deficiencies × pomalidomide × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡